NCT03100318View on ClinicalTrials.gov

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

April 25, 2018

Study Completion Date

August 31, 2018

Conditions
Hyperuricemia With or Without Gout
Interventions
DRUG

FYU-981

Oral daily dosing for 14 weeks

DRUG

Benzbromarone

Oral daily dosing for 14 weeks

Trial Locations (1)

Unknown

Tokyo, Tokyo

Sponsors
All Listed Sponsors
collaborator

Mochida Pharmaceutical Company, Ltd.

INDUSTRY

lead

Fuji Yakuhin Co., Ltd.

INDUSTRY